Highlights
- Cipla shares traded 0.85% higher at ₹1,503.60 following the launch of its new injectable therapy Yurpeak®.
- Tata Steel stock moved up 1.04% to ₹163.92 after approving the acquisition of a majority stake in TPPL.
- DCM Shriram surged 8.81% to ₹1,313.00 after signing an MoU with Bayer Crop Science.
Shares of Cipla, Tata Steel and DCM Shriram witnessed upward movement during the trading session on 11 December 2025, driven by business announcements including a product launch, a strategic acquisition and a new partnership. Here is a detailed overview of the stock price activity and related corporate updates.
Cipla Gains After Launch of Weekly Injectable Therapy
Cipla Limited (NSE:CIPLA) recorded a 0.85% rise in its share price, trading at ₹1,503.60 during the session on 11 December 2025. The move followed the company’s announcement of the launch of Yurpeak® (tirzepatide), a once-weekly injectable therapy indicated for obesity and type 2 diabetes mellitus.
The company has obtained rights to distribute and promote Yurpeak®, the second tirzepatide brand from Lilly to enter the Indian market after DCGI approval. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors and is intended to be used as an adjunct to diet and exercise for adult patients with type 2 diabetes or chronic weight management requirements.
Yurpeak® will be available by prescription in Cipla’s KwikPen® device format in six dosage strengths—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg—offering multiple dosing options for clinicians and patients.
Tata Steel Rises After Approving TPPL Acquisition
Tata Steel Limited (NSE:TATASTEEL) saw its stock trade 1.04% higher at ₹163.92 after the company’s Board approved the acquisition of a 50.01% equity stake in Thriveni Pellets Private Limited (TPPL) for up to ₹636 crore.
Prior to the transaction, the entire 50.01% stake was held by Thriveni Earthmovers Private Limited (TEMPL), while the remaining 49.99% was owned by Lloyds Metals & Energy Limited (LMEL). Following the acquisition, Tata Steel will hold 50.01% of TPPL, with LMEL continuing to retain its 49.99% share.
TPPL’s recent financials show a turnover of ₹2,479.34 crore in FY 2024-25, along with a net worth of ₹1,472.80 crore. Profit after tax stood at (₹45.14 crore) for FY 2024-25.
DCM Shriram Jumps After MoU with Bayer Crop Science
DCM Shriram Limited (NSE:DCMSHRIRAM) traded significantly higher at ₹1,313.00, rising 8.81% after signing a Memorandum of Understanding (MoU) with Bayer Crop Science Limited.
The collaboration will focus on areas such as agri-inputs, digital advisory support, sustainable farming practices and value-chain enhancements. Both companies will also explore opportunities in seeds, plant nutrition, biologicals, digital tools and integrated crop management, along with potential synergies in chemicals and sustainability-linked initiatives including soil health and carbon-sequestration pilots.